TD Securities (USA)’s Alexion Pharmaceuticals ALXN Stock Holding History

TD Securities (USA)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$7K	Hold	51	–	–	0.06%	146
2015 Q4	$10K	Sell	51 -78	-60%	-$13.6K	0.09%	102
2015 Q3	$20K	Sell	129 -90,549	-100%	-$16.5M	0.18%	125
2015 Q2	$16.4M	Buy	90,678 +18,058	+25%	+$3.12M	0.22%	111
2015 Q1	$12.6M	Sell	72,620 -2,676	-4%	-$484K	0.19%	127
2014 Q4	$13.9M	Buy	75,296 +6,102	+9%	+$1.13M	0.2%	122
2014 Q3	$11.5M	Buy	69,194 +48	+0.1%	+$7.88K	0.19%	131
2014 Q2	$10.8M	Buy	69,146 +4,226	+7%	+$667K	0.17%	147
2014 Q1	$9.88M	Sell	64,920 -4,257	-6%	-$677K	0.18%	141
2013 Q4	$9.21M	Buy	69,177 +2,221	+3%	+$267K	0.16%	158
2013 Q3	$7.78M	Buy	66,956 +416	+0.6%	+$45.6K	0.15%	164
2013 Q2	$6.14M	Buy	+66,540	New	+$6.41M	0.12%	198

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

TD Securities (USA)'s ALXN Position: Q1 2016 in Review

TD Securities (USA) held its Alexion Pharmaceuticals (ALXN) position steady in Q1 2016 at 51 shares worth $7K. The position accounts for 0.06% of the portfolio, ranked #146.

TD Securities (USA) first reported a position in ALXN in Q2 2013 and has held it in 12 quarters since. The position peaked at $16.4M in Q2 2015. 519 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

TD Securities (USA) held 51 shares of Alexion Pharmaceuticals worth $7K as of Q1 2016.
TD Securities (USA) left its Alexion Pharmaceuticals share count unchanged in Q1 2016.
Alexion Pharmaceuticals made up 0.06% of TD Securities (USA)'s portfolio in Q1 2016, its #146 holding.
TD Securities (USA) first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
TD Securities (USA)'s Alexion Pharmaceuticals position peaked at $16.4M in Q2 2015.
519 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on TD Securities (USA)'s 13F filing for Q1 2016, filed 27 Apr 2016.